Artificial intelligence (AI) has the potential to become a transformative tool in the field of drug discovery, offering unprecedented capabilities to expedite the identification and development of novel therapeutics. Through advanced computational algorithms and data-driven approaches, AI can impact the drug discovery pipeline in various stages, including target identification, drug repurposing, and clinical trial optimization, leading to faster development timelines, reduced costs, and improved treatment outcomes. However, successful integration of AI in drug discovery requires not only collaboration between computational scientists, domain experts, and experimentalists but also access to deep, multimodal, "AI-ready" data. In this talk we will discuss Owkin approach to AI-driven drug discovery and its mission to ensure every patient gets the right treatment.